Literature DB >> 18612532

Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.

Elaine M Hylek1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612532     DOI: 10.1160/TH08-06-0343

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  5 in total

1.  Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients.

Authors:  Henrica N A M van Breugel; Sandro Gelsomino; Pieter W J Lozekoot; Ryan E Accord; Fabiana Lucà; Orlando Parise; Harry J G M Crijns; Jos G Maessen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-13

Review 2.  Atrial fibrillation and heart failure in the elderly.

Authors:  Pedram Kazemian; Gavin Oudit; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

3.  To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.

Authors:  Serena Granziera; Giulia Bertozzo; Vittorio Pengo; Lucia Marigo; Gentian Denas; Florinda Petruzzellis; Katia Rossi; Tiziana Infante; Seena Jose Padayattil; Egle Perissinotto; Enzo Manzato; Giovanni Nante
Journal:  Intern Emerg Med       Date:  2015-04-21       Impact factor: 3.397

Review 4.  Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making.

Authors:  Yishen Wang; Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2014-02

5.  Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis.

Authors:  Gaetano Piccinocchi; Matteo Laringe; Bruno Guillaro; Giovanni Arpino; Roberto Piccinocchi; Gerardo Nigro; Paolo Calabrò
Journal:  Clin Drug Investig       Date:  2012-11       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.